DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimizing risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionizing liver models for efficacy and toxicology screening, utilizing a platform that enables the large-scale generation of hepatocyte-like cells (HLCs) with functional relevance comparable to human primary cells. Our HLCs effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our HLCs successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.